United States

Back to map

Showing 291-300 of 346 grants

Title Institution Researcher Program Duration Total Award Amount
Discovering early diagnostic markers of cardiovascular disease risk with lipidomics in a 30-year longitudinal prospective type 1 diabetes cohort University of Wisconsin-Madison (Board of Regents University of Wisconsin System) Judith Simcox Improving Lives 01-November-2022 to 04-May-2026 $799.988,63
Using genetics to better diagnose and treat adult-onset T1D in multi-ethnic US population Geisinger Clinic David Carey Cures 01-November-2022 to 30-September-2026 $1.469.640,10
A Multi-task Learning Framework for Developing Genetic Risk Score (GRS) Models of T1D for Multi-Ethnic Population University of Washington Shuai Huang Cures 01-August-2022 to 31-August-2025 $286.892,45
Improving prediction of T1D risk by establishing a self-administered CGM-based technology and whole genome-based polygenic risk scores in diverse populations Rector & Visitors of the University of Virginia Leon Farhy Cures 01-August-2022 to 31-July-2025 $599.999,66
Phenotyping RElatives of persons with Diabetes with CGM and Tests of beta-cell function and health (PREDICT): an integrated longitudinal assessment of deep metabolic phenotyping and CGM metrics in youth at risk for T1D Yale University Alfonso Galderisi Cures 01-February-2023 to 30-September-2026 $747.380,88
PREdictors for DiabetIC Ketoacidosis at Diagnosis of Type 1 Diabetes (The PREDICT study) Rutgers, The State University of New Jersey Chintan Dave Cures 01-August-2022 to 31-July-2026 $695.404,04
Targeting type 1 Diabetes through Polyamines with DFMO Trustees of Indiana University Emily Sims Cures 01-October-2022 to 30-September-2027 $3.693.701,00
Repurposing Cardiorenal Drugs for T1D: Building Evidence from Existing Trials (ReCaRD T1D) AdventHealth Richard Pratley Improving Lives 01-September-2023 to 20-November-2026 $110.840,00
Randomized trial of semaglutide for diabetic kidney disease in type 1 diabetes University of Washington Ian De Boer Improving Lives 01-September-2023 to 31-March-2028 $2.107.411,00
Effectiveness and safety of sotagliflozin in slowing kidney function decline in persons with type 1 diabetes and moderate to severe diabetic kidney disease: The SUGARNSALT Trial Joslin Diabetes Center Inc. Alessandro Doria Improving Lives 01-January-2024 to 31-December-2028 $8.913.450,00